Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor (VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1-3) and other prooncogenic and prooncogenic receptor tyrosine kinases, including fibroblast growth factor receptors (FGFR1-4), platelet derived growth factor receptor α (PDGFRα), KIT, and RET. We examined the antitumor activity of lenvatinib against human thyroid cancer xenograft models in nude mice. Orally administered lenvatinib showed significant antitumor activity in 5 differentiated thyroid cancer (DTC), 5 anaplastic thyroid cancer (ATC), and 1 medullary thyroid cancer (MTC) xenograft models. Lenvatinib also showed antiangiogenesis activity against 5 DTC and 5 ATC xenografts, while lenvatinib showed in vitro antiproliferative activity against only 2 of 11 thyroid cancer cell lines: that is, RO82-W-1 and TT cells. Western blot analysis showed that cultured RO82-W-1 cells overexpressed FGFR1 and that lenvatinib inhibited the phosphorylation of FGFR1 and its downstream effector FRS2. Lenvatinib also inhibited the phosphorylation of RET with the activated mutation C634W in TT cells. These data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Lenvatinib is an oral TKI of VEGFRs, FGFRs, PDGFRα, KIT, and RET.”
From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [22]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
Hanahan, D., & Folkman, J. (1996) · Cell · doi:10.1016/s0092-8674(00)80108-7 · Cited by 6,885
Folkman, J., & Klagsbrun, M. (1987) · Science · doi:10.1126/science.2432664 · Cited by 3,491
Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
Druker, B. J., Tamura, S., Buchdunger, E., Ohno, S., Segal, G. M., Fanning, S., Zimmermann, J., & Lydon, N. B. (1996) · Nature Medicine · doi:10.1038/nm0596-561 · Cited by 2,967
Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A
Mulligan, L. M., Kwok, J. B. J., Healey, C. S., Elsdon, M. J., Eng, C., Gardner, E., Love, D. R., Mole, S. E., Moore, J. K., Papi, L., et al. (1993) · Nature · doi:10.1038/363458a0 · Cited by 1,966
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Brose, M. S., Nutting, C. M., Jarzab, B., Elisei, R., Siena, S., Bastholt, L., de la Fouchardiere, C., Pacini, F., Paschke, R., Shong, Y. K., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60421-9 · Cited by 1,663
Wells, S. A., Robinson, B. G., Gagel, R. F., Dralle, H., Fagin, J. A., Santoro, M., Baudin, E., Elisei, R., Jarzab, B., Vasselli, J. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.5040 · Cited by 1,559
Molecular pathogenesis and mechanisms of thyroid cancer
Xing, M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3431 · Cited by 1,426
Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC
Donis-Keller, H., Dou, S., Chi, D., Carlson, K. M., Toshima, K., Lairmore, T. C., Howe, J. R., Moley, J. F., Goodfellow, P., & Wells, S. A. (1993) · Human Molecular Genetics · doi:10.1093/hmg/2.7.851 · Cited by 1,303
Research works printed but not linked: 1
- 2002, Cancer Research, 62, 5749
Cited by
Items 401–500 of 505
Kang, H. Y., & Lee, H. W. (2021) · International Journal of Gastrointestinal Intervention · doi:10.18528/ijgii210046 · Cited by 1
Radionuclide Therapy of Thyroid Tumors
Elisei, R., Agate, L., Mazzarri, S., Bottici, V., Guidoccio, F., Molinaro, E., Boni, G., Ferdeghini, M., & Mariani, G. (2017) · Springer eBooks · doi:10.1007/978-3-319-26236-9_49 · Cited by 1
Tao, Y. (2023) · Journal of Clinical Images and Medical Case Reports · doi:10.52768/2766-7820/2264 · Cited by 1
Durable Control of Multi-Refractory HBV-HCC with Bevacizumab/Sintilimab/Lenvatinib Triplet Therapy
Wang, J., Wang, J., & Chen, J. (2025) · Cancer Management and Research · doi:10.2147/cmar.s547885 · Cited by 1
Guan, R., Yu, C., Li, S., Mei, J., Wei, W., & Guo, R. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.998534 · Cited by 1
Luo, W.-H., Li, S., & Wang, X. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i11.2033 · Cited by 1
Xu, Z., Wang, Y., Liu, G., Chen, J., Wang, W., Cheng, Y., Ren, Q., Cui, Y., Yang, W., Liu, Z., et al. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2067528 · Cited by 1
Nawa, T., Katayama, K., Kiyota, R., Imai, T., Abe, Y., Hasegawa, N., Takada, R., Fukutake, N., Ikezawa, K., Sakakibara, M., et al. (2019) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-019-01021-6 · Cited by 1
Kumagai, M., Nagahama, M., Akamine, Y., Ozeki, T., Suzuki, A., Sugino, K., Ito, K., & Miura, M. (2022) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10114 · Cited by 1
Okusaka, T., Kudo, M., Ikeda, K., Ikeda, M., Okita, K., Sugawara, M., Tamai, T., Ren, M., Saito, K., & Kumada, H. (2022) · Hepatology Research · doi:10.1111/hepr.13800 · Cited by 1
[New progress in the first-line treatment of advanced hepatocellular carcinoma].
Zhang, C. H., Yao, D. Y., Liu, S., Yang, L. L., & Jin, Z. J. (2024) · PubMed Central · doi:10.3760/cma.j.cn501113-20231114-00193 · Cited by 1
Prolonged duration of response in lenvatinib responders with thyroid cancer (Russian translation)
Gianoukakis, A. G., Dutcus, C. E., Batty, N., Guo, M., & Baig, M. (2018) · Head and neck tumors (HNT) · doi:10.17650/2222-1468-2018-8-3-53-60 · Cited by 1
Tian, Y., Lei, T., Ruan, Q., Zhou, X., Shen, R., Xie, T., Li, S., Cai, X., & Chen, M. (2026) · Cancer Medicine · doi:10.1002/cam4.71756 · Cited by 1
Lu, H., Hu, G., Huang, Z., Wang, N., Xie, F., Han, D., & Ge, J. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.152571 · Cited by 1
Topcu, G. G., Aysan, A., Dik, Ş., Şeker, M., Bahçekapili, M. B., Topkaraoğlu, S., Yavuzer, D., & Yağcı, T. (2025) · TURKISH JOURNAL OF BIOLOGY · doi:10.55730/1300-0152.2739 · Cited by 1
AISHA, A., Sajjad, A., Munawar, N., Azam, H. M. H., Ishtiaq, U., & NAWAZ, S. (2025) · Asian Journal of Natural Product Biochemistry · doi:10.13057/biofar/f230104 · Cited by 1
Kimura, M., Yamada, S., Go, M., Yasuda, S., Toyoda, H., & Usami, E. (2024) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552241281900 · Cited by 1
Nakamura, T., Yoshida, T., Masuda, K., Sato, J., Shinno, Y., Matsumoto, Y., Okuma, Y., Goto, Y., Horinouchi, H., Yamamoto, N., et al. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100872 · Cited by 1
Roy, P., & Parthasarathy, K. M. (2023) · Journal of Cancer Research and Therapeutics · doi:10.4103/jcrt.jcrt_1251_21 · Cited by 1
Zhao, Y., Wang, Y., Zhao, W., chen, L. Y., Chen, H., Song, Y., Tang, Y., Li, H., & Yao, P. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.05.005 · Cited by 1
Latorre, A., Fioretti, A. M., Giotta, F., & Lorusso, V. (2019) · Future Oncology · doi:10.2217/fon-2019-0114 · Cited by 1
Ulcerative skin lesion of the thigh caused by lenvatinib subscribed for hepatocellular carcinoma
Dohmen, K., Onohara, S.-Y., & Shimoda, S. (2020) · Kanzo · doi:10.2957/kanzo.61.191 · Cited by 1
Ikeda, Y., Ueno, M., Takabatake, H., Uenishi, Y., Togawa, A., Hata, A., Mano, T., Kayahara, T., Morimoto, Y., & Mizuno, M. (2021) · Kanzo · doi:10.2957/kanzo.62.742 · Cited by 1
Ishikawa, T., Hasegawa, I., Hirosawa, H., Honmou, T., SAKAI, N., IGARASHI, T., Yamazaki, S., Kobayashi, T., Sato, T., Iwanaga, A., et al. (2023) · In Vivo · doi:10.21873/invivo.13150 · Cited by 1
Lou, S., Sun, W., & Wu, Y. (2018) · Oncology and Translational Medicine · doi:10.1007/s10330-018-0305-5 · Cited by 1
Takahashi, S., Tahara, M., Ito, K., Tori, M., Kiyota, N., Yoshida, K., Sakata, Y., & Yoshida, A. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01829-0 · Cited by 1
Targeted Therapy and Immunotherapies in Hepatocellular Carcinoma: Mechanisms and Clinical Studies
He, P. C., Xie, S., Xie, K., Gao, F., Cai, Y., Huang, Y., Liu, C., Wu, H., Lyu, Y., & Lan, T. (2026) · MedComm · doi:10.1002/mco2.70694
Sui, W. F., li, J. Y., & Fu, J. (2020) · Research Square · doi:10.21203/rs.3.rs-68877/v1
Kumagai, M., Nagahama, M., Akamine, Y., Ozeki, T., Suzuki, A., Sugino, K., Ito, K., & Miura, M. (2021) · Research Square · doi:10.21203/rs.3.rs-828572/v2
2021 Update on gynecologic cancer
Dioun, S. M. (2021) · OBG Management · doi:10.12788/obgm.71
Étude du récepteur SLAMF3 : mécanismes et stratégies thérapeutiques dans les cancers solides
Fouquet, G. (2018) · theses.fr (ABES) · doi:10.70675/d78c0102z9408z4368zad7cz6fd81d60cb19
Zhao, X., Yan, S., Meng, J., & Wang, L. (2026) · Hepatology Research · doi:10.1111/hepr.70164
Wasnik, D., Swamy, K. V., & Vyas, R. (2026) · Advanced Biology · doi:10.1002/adbi.70156
Zhang, L., Zhang, Q., Zhang, X., Mao, A., Liu, Y., & Luo, H. (2026) · MedComm – Future Medicine · doi:10.1002/mef2.70051
Zhao, L., Zhang, Z., Wang, D., Liu, Y., Liu, Z., & Lou, C. (2024) · Research Square · doi:10.21203/rs.3.rs-5424736/v1
Ma, L., Liu, H., Pan, D., Qin, X., Gao, Y., Ma, X., Yü, A., Liu, D., Zhang, X., & Han, Z. (2023) · Research Square · doi:10.21203/rs.3.rs-3579907/v1
Chen, R., Li, Q., Xu, S., Ye, C., Tian, T., Jiang, Q., Shan, J., & Ruan, J. (2022) · Figshare · doi:10.6084/m9.figshare.19164478
Imamura, H., Chiang, S., Kuronishi, M., Funahashi, Y., Nishino, T., & Yachie‐Kinoshita, A. (2026) · Cancers · doi:10.3390/cancers18071067
Self-citationPatel, R. P., & Varghese, J. F. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-93894-8_9
Barizi, A. Z. M. (2024) · Universiti Putra Malaysia Institutional Repository (Universiti Putra Malaysia)
Fundamentos de farmacología oncológica
del Azuay, U., Barrera, E. C., Duque, G., & del Azuay, U. (2020) · doi:10.33324/ceuazuay.72
Radionuclide Therapy of Thyroid Tumors
Elisei, R., Agate, L., Mazzarri, S., Bottici, V., Guidoccio, F., Molinaro, E., Boni, G., Ferdeghini, M., & Mariani, G. (2016) · Springer eBooks · doi:10.1007/978-3-319-26067-9_49-1
Chen, L., Wang, P., Wang, H., Zhao, Y., Wang, F., Zhu, Y., Xu, M., Zhang, Y., Wang, K., Wang, S., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3228233/v1
Rearranged during transfection (RET) inhibitors
Shrivastava, V., Gurjar, V. K., Jain, S., Vaidya, A., & Sharma, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-96121-9.00013-9
Azhar, M. Y. (2018) · Thesis Commons (OSF Preprints) · doi:10.31237/osf.io/gqcj9
Radionuclide Therapy of Thyroid Tumors
Elisei, R., Agate, L., Mazzarri, S., Bottici, V., Guidoccio, F., Molinaro, E., Boni, G., Ferdeghini, M., & Mariani, G. (2022) · Springer eBooks · doi:10.1007/978-3-319-26067-9_49-2
Radionuclide Therapy of Thyroid Tumors
Elisei, R., Agate, L., Mazzarri, S., Bottici, V., Guidoccio, F., Molinaro, E., Boni, G., Ferdeghini, M., & Mariani, G. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_49
Laçin, Ş., & Yalçın, Ş. (2024) · Springer eBooks · doi:10.1007/978-3-031-56968-5_23
Combination therapy regimens in the treatment of metastatic renal cell carcinoma: A review
Zukov, R. A., Chernyaev, D. V., & Zulkaidarova, A. R. (2022) · Journal of Modern Oncology · doi:10.26442/18151434.2022.2.201720
Tanriverdi, A. M. (n.d.) · Marmara University Open Access System
Cardiovascular safety liabilities of VEGFR-2 inhibitors
Pannucci, P. (2024)
Chalas, E. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.737547356.793578670
Neuerungen in der Systemtherapie des Anaplastischen Schilddrüsenkarzinoms
Dierks, C., Vordermark, D., & Lorenz, K. (2022) · TumorDiagnostik & Therapie · doi:10.1055/a-1744-2100
Kudo, M., Vogel, A., Evans, T. R. J., Ma, Y. T., Daniele, B., Baron, A. D., Mahipal, A., Qin, S., Blanc, J. F., López, C., et al. (2026) · Liver Cancer · doi:10.1159/000553375
Shiraishi, C., Kato, H., Asai, Y., & Iwamoto, T. (2026) · Cancer Reports · doi:10.1002/cnr2.70461
ROR1 CAR T cells and lenvatinib cooperatively target anaplastic thyroid carcinomaPreprint
Dierks, C., Skorobohatko, O., Chernyakov, D., Höfler, S., Benkler, T., Bräuer-Hartmann, D., Müller, T., Edemir, B., Willscher, E., Trojanowicz, B., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-8690827/v1
Place du lenvatinib dans les cancers thyroïdiens réfractaires à l’iode
de la Fouchardière, C. (2016) · Bulletin du Cancer · doi:10.1016/j.bulcan.2016.10.002
Tahara, M., Brose, M. S., Wirth, L. J., Suzuki, T., Miyagishi, H., Fujino, K., Dutcus, C. E., & Gianoukakis, A. G. (2019) · Head and neck tumors (HNT) · doi:10.17650/2222-1468-2019-9-1-38-50
Tomonari, T., Sato, Y., Tanaka, H., Tanaka, T., Fujino, Y., Mitsui, Y., Hirao, A., Taniguchi, T., Sogabe, M., Okamoto, K., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.01.03.893800
Self-citationOsteonecrosis of the Jaw during Lenvatinib Therapy: A Case Report Based on Surgical Management
Udagawa, G., Okamoto, T., Kaibuchi, N., Sangu, N., Kagawa, C., & Ando, T. (2019) · Institutional Repositories DataBase (IRDB) · doi:10.24488/twmuj.2019002
Hamieh, L., Beck, R. L., Le, V. H., & Hsieh, J. J. (2020) · Cancer Urology · doi:10.17650/1726-9776-2020-16-3-53-61
Saito, N., Hatanaka, T., Nakano, Y., Yoshida, S., Hachisu, Y., Tanaka, Y., Yoshinaga, T., Kubota, J., Tokue, H., Shibuya, K., et al. (2020) · Kanzo · doi:10.2957/kanzo.61.588
Kosaka, Y., Kawaoka, T., Ogawa, Y., Amioka, K., Naruto, K., Yoshikawa, Y., Ando, Y., Suehiro, Y., Yamaoka, K., Fujii, Y., et al. (2021) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-021-01481-9
Potential of combination therapy with lenvatinib and radiation for thyroid cancer
Suzuki, K., Iwai, H., Utsunomiya, K., Kono, Y., Kobayashi, Y., Yun, Y., Mitani, A., Fukui, K., Sakai, H., Tanigawa, N., et al. (2022) · The Journal of Kansai Medical University · doi:10.5361/jkmu.73.1
Wang, P., Li, L., Liu, Y., Shi, Y., Zhang, X., & Wu, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1720670
Shiraiwa, K., Tanaka, R., Sueshige, Y., Ashikari, Y., Abe, H., Tatsuta, R., & Itoh, H. (2026) · Research Square · doi:10.21203/rs.3.rs-9631847/v1
Suzuki, K., Otoyama, Y., Matsumoto, N., Masuo, Y., Nakajima, Y., Sugiura, I., Fuji, T., Nomura, E., Ichikawa, Y., Shimozuma, Y., et al. (2026) · Clinical Pharmacokinetics · doi:10.1007/s40262-026-01662-0
(2024) · International Research Journal of Modernization in Engineering Technology and Science · doi:10.56726/irjmets59803
Lee, J., Hasegawa, K., Kim, B., Berman, B. S., Suzuki, S., Corr, B. R., Yunokawa, M., Orr, D., Yamamoto, N., Soliman, P. T., et al. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.104206
Self-citationIdentifizierung und Charakterisierung koronarer Gefäßwand-residenter Stammzellen
Löw, K. (2021) · Online Publication Service of Würzburg University (Würzburg University) · doi:10.25972/opus-22340
Ben Khaled, N. (2025) · Electronic Theses of LMU Munich (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.35943
Breakthrough and Boundaries in Management of Hepatocellular Carcinoma by Immunotherapy
Shukla, V., Leonn, J. S., & Sandrugu, R. S. (2025) · International Journal of Innovative Science and Research Technology (IJISRT) · doi:10.38124/ijisrt/25dec575
이용상 (2018) · YUHSpace (Yonsei University Medical Library)
Investigating the role of FGF signaling in left-right determination
Little, R. B. (2021) · Oxford University Research Archive (ORA) (University of Oxford) · doi:10.5287/ora-zbdjx4oaw
肝細胞癌患者におけるレンバチニブの治療効果ならびに副作用発現に対する薬物血中濃度モニタリングの有用性に関する研究
秦, 晃. (2021) · Institutional Repositories DataBase (IRDB)
Nishida, N., Ueshima, K., Aoki, T., Matsubara, T., Omaru, N., Okai, N., Morita, M., Chishina, H., Takita, M., Hagiwara, S., et al. (2026) · Hepatology Research · doi:10.1111/hepr.70126
The significance of microsatellite instability in endometrial cancer
Anca-Stanciu, M.-B., Maier, C., & Brătilă, E. (2021) · Obstetrica şi Ginecologia · doi:10.26416/obsgin.69.3.2021.5556
Current perspectives on the pharmacotherapeutic management of anaplastic thyroid cancer
Elia, G., Ferrari, S. M., Ragusa, F., Balestri, E., Mazzi, V., Botrini, C., Rugani, L., Carlo, G. D., Baglini, A., Rizzi, R., et al. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2760632
Some Advanced Thyroid Cancer Patients Have a Prolonged Response to Lenvatinib
Kim, B. W. (2018) · Clinical Thyroidology · doi:10.1089/ct.2018;30.305-308
Song, E., & Kim, W. G. (2018) · International Journal of Thyroidology · doi:10.11106/ijt.2018.11.2.78
Gristina, V., Barraco, N., Buscemi, S., Incorvaia, L., & Berruti, A. (2021) · UNIPA Springer series · doi:10.1007/978-3-030-56051-5_56
He, M., Huang, Y., Du, Z., Lai, Z., Ouyang, H., Shen, J., Wen, D., Li, Q., Zhang, Y., Wei, W., et al. (2023) · doi:10.1158/1078-0432.24826117
Wang, B., & Ma, J. (2023) · Clinical Imaging and Case Reports · doi:10.52338/cicasrep.2022.1009
Yamamoto, S., Fukata, S., Karashima, T., Kurabayashi, A., Yoshimura, R., Furihata, K., Shiba, Y., Nao, T., Satake, H., & Inoue, K. (2025) · Urology Case Reports · doi:10.1016/j.eucr.2025.103140
Ripretinib-related pyoderma gangrenosum: first description and pathophysiological clues
Valerio, M., Valentin, T., & Sibaud, V. (2025) · Annales de Dermatologie et de Vénéréologie · doi:10.1016/j.annder.2025.103410
He, M.-K., Liang, R.-B., Zhao, Y., Xu, Y.-J., Chen, H.-W., Zhou, Y.-M., Lai, Z.-C., Xu, L., Wei, W., Zhang, Y.-J., et al. (2021) · Figshare · doi:10.25384/sage.14316364
Phosphoglucomutase 5 and hepatocellular carcinoma
Martinez Rodriguez, V. (2024) · ScholarSpace (University of Hawaii at Manoa)
Rodrigues, R., Pires, C., Martins, C., Leite, V. A. P. H., da Silva, T. N., & Cavaco, B. M. (2026) · Endocrine · doi:10.1007/s12020-025-04541-z
鈴木, 健. (2021) · Institutional Repositories DataBase (IRDB)
Ablinger, C., Huber‐Cantonati, P., Weber, D. D., Pichler, S., Schischkow, G., Garcia‐Miralles, M., Pirich, C., Rendl, G., Kiener, T. A., Felder, T. K., et al. (2026) · International Journal of Cancer · doi:10.1002/ijc.70526
Xu, B., Pan, Q., Li, S., Peng, R., Zhang, L., Li, H., Yu, S., & Zhang, X. (2026) · BMC Medicine · doi:10.1186/s12916-026-05154-7
Metadata
- Authors
- Tohyama, O., Matsui, J., Kodama, K., Hata-Sugi, N., Kimura, T., Okamoto, K., Minoshima, Y., Iwata, M., & Funahashi, Y.
- Affiliations
- Eisai (Japan) (JP)
- Eisai (United States) (US)
- Corresponding author
- Funahashi, Yasuhiro
- ORCID
- Venue
- Journal of Thyroid Research
- Publisher
- Wiley
- Published
- 2014
- Volume
- 2014
- Pages
- 1-13
- ISSN
- 2042-0072 (ISSN-L)
- 2090-8067
- PMC
- PMC4177084
- OpenAlex
- W2094109552
- Cited by
- 475
- References
- 50
- Citations by year
- 2026: 18 · 2025: 22 · 2024: 49 · 2023: 69 · 2022: 57 · 2021: 69 · 2020: 52 · 2019: 53 · 2018: 38 · 2017: 17 · 2016: 18 · 2015: 12 · 2014: 1
- FWCI
- 13.15
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Thyroid Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- lenvatinib, thyroid cancer, angiogenesis inhibition, VEGF receptor signaling, FGFR1, RET, receptor tyrosine kinase inhibitors, anaplastic thyroid carcinoma, medullary thyroid carcinoma, differentiated thyroid cancer, xenograft models, antiproliferative activity, FRS2, KIT, PDGFRA
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.